Wells Fargo & Company MN lifted its position in shares of MyoKardia, Inc. (NASDAQ:MYOK) by 2.5% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 18,539 shares of the biotechnology company’s stock after purchasing an additional 455 shares during the period. Wells Fargo & Company MN owned 0.06% of MyoKardia worth $243,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the company. Fiduciary Trust Co. boosted its holdings in shares of MyoKardia by 7.2% during the second quarter. Fiduciary Trust Co. now owns 30,612 shares of the biotechnology company’s stock worth $401,000 after purchasing an additional 2,058 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of MyoKardia by 103.5% during the second quarter. JPMorgan Chase & Co. now owns 476,575 shares of the biotechnology company’s stock worth $6,243,000 after purchasing an additional 242,408 shares during the period. Swiss National Bank boosted its holdings in shares of MyoKardia by 25.7% during the second quarter. Swiss National Bank now owns 31,790 shares of the biotechnology company’s stock worth $416,000 after purchasing an additional 6,500 shares during the period. Marshall Wace North America L.P. boosted its holdings in shares of MyoKardia by 28.0% during the second quarter. Marshall Wace North America L.P. now owns 155,274 shares of the biotechnology company’s stock worth $2,019,000 after purchasing an additional 33,970 shares during the period. Finally, Fernwood Investment Management LLC boosted its holdings in shares of MyoKardia by 11.7% during the second quarter. Fernwood Investment Management LLC now owns 48,393 shares of the biotechnology company’s stock worth $634,000 after purchasing an additional 5,070 shares during the period. Institutional investors own 44.93% of the company’s stock.

A number of analysts have recently weighed in on the stock. Wedbush reissued an “outperform” rating and issued a $51.00 price target on shares of MyoKardia in a research note on Wednesday, September 20th. Credit Suisse Group reissued an “outperform” rating and issued a $55.00 price target (up from $45.00) on shares of MyoKardia in a research note on Tuesday, September 19th. Zacks Investment Research downgraded shares of MyoKardia from a “hold” rating to a “sell” rating in a research note on Wednesday, October 11th. TheStreet downgraded shares of MyoKardia from a “c” rating to a “d+” rating in a research note on Friday, November 3rd. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $65.00 price target (up from $45.00) on shares of MyoKardia in a research note on Monday, August 21st. Two research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $55.00.

MyoKardia, Inc. (NASDAQ MYOK) opened at $36.85 on Tuesday. MyoKardia, Inc. has a one year low of $10.55 and a one year high of $49.55.

MyoKardia (NASDAQ:MYOK) last released its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.42). MyoKardia had a negative net margin of 53.49% and a negative return on equity of 14.92%. The company had revenue of $5.63 million during the quarter, compared to the consensus estimate of $6.10 million. During the same period in the prior year, the firm earned ($0.35) earnings per share. MyoKardia’s revenue was up 58.6% on a year-over-year basis. equities research analysts anticipate that MyoKardia, Inc. will post -1.62 earnings per share for the current fiscal year.

WARNING: “Wells Fargo & Company MN Has $243,000 Stake in MyoKardia, Inc. (MYOK)” was reported by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.dailypolitical.com/2017/11/21/wells-fargo-company-mn-has-243000-stake-in-myokardia-inc-myok.html.

In other MyoKardia news, Director Kevin P. Starr sold 601,400 shares of the firm’s stock in a transaction that occurred on Tuesday, September 26th. The shares were sold at an average price of $43.00, for a total transaction of $25,860,200.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Anastasios Gianakakos sold 4,300 shares of the firm’s stock in a transaction that occurred on Monday, November 6th. The shares were sold at an average price of $40.23, for a total transaction of $172,989.00. Following the transaction, the chief executive officer now directly owns 513,417 shares of the company’s stock, valued at approximately $20,654,765.91. The disclosure for this sale can be found here. Insiders have sold 1,713,513 shares of company stock valued at $72,678,568 in the last ninety days. Insiders own 33.40% of the company’s stock.

MyoKardia Profile

MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.

Institutional Ownership by Quarter for MyoKardia (NASDAQ:MYOK)

Receive News & Ratings for MyoKardia Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MyoKardia Inc. and related companies with MarketBeat.com's FREE daily email newsletter.